Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Cash & Equivalents	162,334	219,433	125,022	268,651	458,975	45,976
Short-Term Investments	80,542	9,381	176,390	25,584	-	2,423
Trading Asset Securities	-	-	-	9,035	377.68	-
Cash & Short-Term Investments	242,875	228,815	301,412	303,270	459,353	48,399
Cash Growth	-5.41%	-24.09%	-0.61%	-33.98%	849.10%	391.62%
Accounts Receivable	3,789	391.6	132.72	-	-	-
Receivables	3,789	391.6	132.72	-	-	-
Inventory	18,505	18,103	7,146	2,157	-	-
Prepaid Expenses	2,987	2,733	2,731	-	-	1,412
Other Current Assets	1,126	309.41	53.44	6,139	584.08	-
Total Current Assets	269,283	250,352	311,476	311,566	459,937	49,811
Property, Plant & Equipment	342,597	327,062	310,438	38,342	6,437	4,519
Long-Term Investments	-	-	-	74,710	24,159	9,049
Goodwill	11,412	10,785	10,192	-	-	-
Other Intangible Assets	33,177	31,327	29,877	4,288	450.33	386.92
Long-Term Deferred Charges	99,324	91,643	78,843	61,024	108,573	94,624
Other Long-Term Assets	665.84	551.5	775.14	9,883	4,611	1,709
Total Assets	756,458	711,720	741,600	499,813	604,166	160,098
Accounts Payable	4,917	2,282	462.15	2,624	-	-
Accrued Expenses	6,215	5,975	6,150	4,923	3,552	1,099
Short-Term Debt	134,847	15,439	31,188	-	2,873	-
Current Portion of Long-Term Debt	-	47,845	31,176	-	-	-
Current Portion of Leases	1,245	950.81	1,682	1,593	1,326	443.84
Current Unearned Revenue	-	-	-	-	565	231.5
Other Current Liabilities	36,118	73,366	64,231	32,654	5,730	6,702
Total Current Liabilities	183,342	145,857	134,888	41,794	14,046	8,477
Long-Term Debt	38,085	40,247	50,190	-	-	61.26
Long-Term Leases	941.1	624.04	1,326	2,656	3,571	2,373
Long-Term Unearned Revenue	-	-	-	25,427	11,588	11,387
Long-Term Deferred Tax Liabilities	8,184	7,755	7,368	-	-	-
Other Long-Term Liabilities	32,511	1,734	1,593	0	-	-
Total Liabilities	263,063	196,219	195,365	69,877	29,206	22,299
Common Stock	772,819	730,340	690,175	679,713	594,072	152,779
Additional Paid-In Capital	-34,428	7,865	7,286	7,175	-	-
Retained Earnings	-332,275	-294,797	-246,151	-259,601	-27,954	-21,891
Comprehensive Income & Other	-15,617	-4,321	-798.76	2,649	8,843	6,911
Total Common Equity	390,499	439,087	450,511	429,936	574,961	137,799
Minority Interest	102,896	76,414	95,724	-	-	-
Shareholders' Equity	493,395	515,502	546,235	429,936	574,961	137,799
Total Liabilities & Equity	756,458	711,720	741,600	499,813	604,166	160,098
Total Debt	175,118	105,106	115,561	4,249	7,771	2,878
Net Cash (Debt)	67,758	123,708	185,851	299,020	451,582	45,521
Net Cash Growth	-53.30%	-33.44%	-37.85%	-33.78%	892.04%	-
Net Cash Per Share	1126.91	2058.50	3092.56	4975.70	8751.18	1067.23
Filing Date Shares Outstanding	300.48	300.48	300.48	300.48	300.48	42.65
Total Common Shares Outstanding	300.48	300.48	300.48	300.48	300.48	42.65
Working Capital	85,941	104,494	176,588	269,771	445,890	41,335
Book Value Per Share	1299.58	1461.28	1499.30	1430.83	1913.47	3230.70
Tangible Book Value	345,910	396,976	410,442	425,647	574,510	137,413
Tangible Book Value Per Share	1151.19	1321.13	1365.95	1416.55	1911.97	3221.62
Land	27,829	27,704	26,567	12,055	-	-
Buildings	135,897	77,472	76,415	-	-	-
Machinery	73,910	72,427	51,848	10,175	3,455	2,809
Construction In Progress	114,069	152,876	169,147	15,415	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.